| First Author | Soria-Tobar L | Year | 2024 |
| Journal | Alzheimers Res Ther | Volume | 16 |
| Issue | 1 | Pages | 233 |
| PubMed ID | 39438925 | Mgi Jnum | J:359218 |
| Mgi Id | MGI:7785618 | Doi | 10.1186/s13195-024-01600-x |
| Citation | Soria-Tobar L, et al. (2024) Blockade of brain alkaline phosphatase efficiently reduces amyloid-beta plaque burden and associated cognitive impairment. Alzheimers Res Ther 16(1):233 |
| abstractText | BACKGROUND: Alzheimer's disease (AD) is the most prevalent neurodegenerative disease. Three new drugs for AD based on monoclonal antibodies against the amyloid-beta peptide (Abeta) have recently been approved because they favor the reduction of the burden of senile plaque in the AD patient's brain. Nonetheless, both drugs have very limited applicability and benefits and show several side effects. These limitations invite us to find alternative strategies for treating patients with AD. Here, we explored whether tissue-nonspecific alkaline phosphatase (TNAP), an ectoenzyme upregulated in the brain of AD patients and whose inhibition has beneficial effects on tau-induced pathology, is also efficient in reducing senile plaque burden. METHODS: To evaluate whether TNAP may reduce cerebral senile plaque loading and Abeta-related toxicity, we use both pharmacological and genetic approaches. We analyze postmortem samples from human AD patients, APP/PS1 mice (a mouse model that mimics amyloid pathology observed in AD patients) treated or not with TNAP inhibitors, and the newly generated transgenic mouse line, TNAP-deficient APP/PS1 mice. RESULTS: For the first time, we describe that genetic or pharmacological blockade of TNAP effectively reduces senile plaque burden by promoting its clearance, which leads to amelioration of cognitive impairment caused by Abeta-induced toxicity. These beneficial effects of TNAP inhibition occur concomitantly with higher microglial recruitment toward the senile plaque and increased microglial phagocytic capacity of Abeta by a mechanism involving metalloprotease-depending osteopontin processing. In addition, we also found that TNAP blockade favors LRP1-mediated transport of Abeta through the BBB. CONCLUSIONS: Here, we have shown that TNAP inhibition effectively reduces brain senile plaque burden and associated behavioral defects. Furthermore, given that we had previously reported that TNAP blockade also ameliorates Tau-induced neurotoxicity and increases lifespan of P301S tauopathy mouse model, we can state that TNAP blockade may be a novel and efficient therapy for treating patients with AD. |
